Jennifer Serwanga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jennifer Serwanga has a total of 237 co-authors. Here are the top co-authors by number of shared publications:
Pontiano Kaleebu
Uganda Virus Research Institute (UVRI), Entebbe, Uganda; MRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda; 3. London School of Hygiene & Tropical Medicine, Keppel Street, London, United Kingdo
32 shared publicationsViolet Ankunda
MRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda
23 shared publicationsGeoffrey Odoch
Uganda Virus Research Institute (UVRI), Entebbe, Uganda; MRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda
20 shared publications- Joseph Ssebwana Katende
Department of Immunology, Uganda Virus Research Institute, Entebbe, Uganda
15 shared publications Laban Kato
Viral Pathogens Theme, MRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda
15 shared publicationsPeter Ejou
Uganda Virus Research Institute (UVRI), Entebbe, Uganda; MRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda
14 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by Springer Nature in Research Square
Preferential Ebola virus glycoprotein recognition 16–17 years after Bundibugyo virus infection
The re-emergence of Bundibugyo virus (BDBV), for which no licensed vaccine is available, has created an urgent need for human immunological evidence to inform evaluation of existing filovirus countermeasures. We measured IgG binding to BDBV, Ebola virus (EBOV)-Mayinga and Sudan virus (SUDV)-Gulu and SUDV-Boniface glycoproteins in 40 PCR-confirmed BDBV survivors sampled 16–17 years after infection. BDBV-specific IgG was detected in 22/40 participants (55.0%), while heterologous recognition was most frequent for EBOV-Mayinga (23/40, 57.5%), compared with SUDV-Gulu (5/40, 12.5%) and SUDV-Boniface (3/40, 7.5%). BDBV and EBOV-Mayinga responses were strongly correlated (Spearman ρ = 0.90), with recognition of both glycoproteins in 20/40 participants (50.0%). In 21 participants with detectable binding, EBOV-Mayinga endpoint titres were significantly higher than BDBV titres and remained positively correlated. These findings support functional evaluation of EBOV-based and broadly reactive filovirus countermeasures for potential relevance to BDBV.
- 26 August 2026
- Published by Springer Nature in Research Square
Open AccessPreferential Ebola virus glycoprotein recognition 16–17 years after Bundibugyo virus infection
The re-emergence of Bundibugyo virus (BDBV), for which no licensed vaccine is available, has created an urgent need for human immunological evidence to inform evaluation of existing filovirus countermeasures. We measured IgG binding to BDBV, Ebola virus (EBOV)-Mayinga and Sudan virus (SUDV)-Gulu and SUDV-Boniface glycoproteins in 40 PCR-confirmed BDBV survivors sampled 16–17 years after infection. BDBV-specific IgG was detected in 22/40 participants (55.0%), while heterologous recognition was most frequent for EBOV-Mayinga (23/40, 57.5%), compared with SUDV-Gulu (5/40, 12.5%) and SUDV-Boniface (3/40, 7.5%). BDBV and EBOV-Mayinga responses were strongly correlated (Spearman ρ = 0.90), with recognition of both glycoproteins in 20/40 participants (50.0%). In 21 participants with detectable binding, EBOV-Mayinga endpoint titres were significantly higher than BDBV titres and remained positively correlated. These findings support functional evaluation of EBOV-based and broadly reactive filovirus countermeasures for potential relevance to BDBV.
- Open Access
- 5 August 2026
- Published by Elsevier in EBioMedicine
- Vol. 131
Lesion viral burden, multidrug-resistant superinfection, and HIV-associated haematological vulnerability in hospitalised clade Ib mpox: a prospective cohort study in Uganda
- 5 August 2026
- Published by Elsevier in EBioMedicine
- Vol. 131
Open AccessLesion viral burden, multidrug-resistant superinfection, and HIV-associated haematological vulnerability in hospitalised clade Ib mpox: a prospective cohort study in Uganda
- Open Access
Preclinical Safety Evaluation of a Replication-Defective Canine Adenovirus Type 2 Vector-Based SARS-CoV-2 Vaccine Candidate in Murine Models
Background: Adenoviral vectors are widely used in vaccine development; however, pre-existing immunity to common human adenovirus serotypes can limit their effectiveness. Canine adenovirus type 2 (CAV-2) is a non-human adenovirus with low seroprevalence in humans, making it a suitable alternative vector. Despite its promise, comprehensive preclinical safety data for CAV-2 vector-based vaccine platforms remain limited. In this study, we evaluated the safety profile of a replication-defective CAV-2 vector expressing the Omicron BA.4 SARS-CoV-2 spike immunogen in BALB/c mouse models. Methods: The SARS-CoV-2 CAV-2 vector-based vaccine was expressed and propagated in AD293 cells. The mice received intramuscular prime-boost immunisations with low (1 × 106 PFU), moderate (0.5 × 1010 PFU), or high (1 × 1010 PFU) vaccine doses, alongside empty CAV-2 vector and physiological buffer control groups, and were monitored longitudinally up to Day 72. The mice were clinically assessed at days 0, 7, 21, 42, and 72 for any deviations from normal conditions in comparison to the control groups. Biochemical analyses were performed to evaluate liver and kidney function, as well as any tissue injury due to the vaccine candidate. Hematological parameters were assessed by conducting complete blood counts. Body temperature and weight changes were also monitored as an indicator of systemic toxicity. Results: The biochemical and haematological parameters remained within physiological reference ranges across all dose groups and timepoints, with no dose-related deviations, indicating that the vaccine candidate did not show evidence of hepatotoxicity, nephrotoxicity, tissue or haematological toxicity. Body temperatures remained within normal physiological ranges following both prime and booster immunisations, and body weights increased normally across all groups as the animals grew throughout the study period without any abnormal weight gain or loss. Conclusions: These results suggest that the replication-defective CAV-2-vectored SARS-CoV-2 vaccine candidate was well tolerated and did not demonstrate evidence of systemic toxicity under the conditions tested. These findings demonstrate that the CAV-2 vector exhibits a favourable safety profile in murine models when used as a vaccine delivery platform, supporting its translational potential as an alternative adenoviral vector-based vaccine platform. Further studies incorporating additional safety endpoints, including histopathological, vector persistence and shedding evaluation, are warranted to support continued development of the platform.
Open AccessPreclinical Safety Evaluation of a Replication-Defective Canine Adenovirus Type 2 Vector-Based SARS-CoV-2 Vaccine Candidate in Murine Models
Background: Adenoviral vectors are widely used in vaccine development; however, pre-existing immunity to common human adenovirus serotypes can limit their effectiveness. Canine adenovirus type 2 (CAV-2) is a non-human adenovirus with low seroprevalence in humans, making it a suitable alternative vector. Despite its promise, comprehensive preclinical safety data for CAV-2 vector-based vaccine platforms remain limited. In this study, we evaluated the safety profile of a replication-defective CAV-2 vector expressing the Omicron BA.4 SARS-CoV-2 spike immunogen in BALB/c mouse models. Methods: The SARS-CoV-2 CAV-2 vector-based vaccine was expressed and propagated in AD293 cells. The mice received intramuscular prime-boost immunisations with low (1 × 106 PFU), moderate (0.5 × 1010 PFU), or high (1 × 1010 PFU) vaccine doses, alongside empty CAV-2 vector and physiological buffer control groups, and were monitored longitudinally up to Day 72. The mice were clinically assessed at days 0, 7, 21, 42, and 72 for any deviations from normal conditions in comparison to the control groups. Biochemical analyses were performed to evaluate liver and kidney function, as well as any tissue injury due to the vaccine candidate. Hematological parameters were assessed by conducting complete blood counts. Body temperature and weight changes were also monitored as an indicator of systemic toxicity. Results: The biochemical and haematological parameters remained within physiological reference ranges across all dose groups and timepoints, with no dose-related deviations, indicating that the vaccine candidate did not show evidence of hepatotoxicity, nephrotoxicity, tissue or haematological toxicity. Body temperatures remained within normal physiological ranges following both prime and booster immunisations, and body weights increased normally across all groups as the animals grew throughout the study period without any abnormal weight gain or loss. Conclusions: These results suggest that the replication-defective CAV-2-vectored SARS-CoV-2 vaccine candidate was well tolerated and did not demonstrate evidence of systemic toxicity under the conditions tested. These findings demonstrate that the CAV-2 vector exhibits a favourable safety profile in murine models when used as a vaccine delivery platform, supporting its translational potential as an alternative adenoviral vector-based vaccine platform. Further studies incorporating additional safety endpoints, including histopathological, vector persistence and shedding evaluation, are warranted to support continued development of the platform.
- Open Access
- 29 June 2026
- Published by Elsevier in The Lancet Microbe
- Vol. 7 (8) , 101395
Saliva versus lesion swabs for PCR diagnosis of acute-phase clade Ib mpox in Uganda: a prospective matched hospital cohort study
- 29 June 2026
- Published by Elsevier in The Lancet Microbe
- Vol. 7 (8) , 101395
Open AccessSaliva versus lesion swabs for PCR diagnosis of acute-phase clade Ib mpox in Uganda: a prospective matched hospital cohort study
- Open Access
- 24 June 2026
- Published by Springer Nature in Tropical Medicine and Health
Severe Clade I (subclade Ib) mpox in advanced HIV complicated by multidrug-resistant bacterial superinfection and ocular involvement: a case report from Uganda
Background: Mpox in people living with HIV (PLHIV) with advanced immunosuppression is poorly understood in sub-Saharan Africa, where high HIV prevalence intersects with limited access to mpox-specific antivirals. Urgent evidence is needed to guide clinical management and improve outcomes for this vulnerable population in resource-limited settings with outbreaks. Case presentation: We report a 30-year-old Ugandan man with advanced HIV (CD4 55 cells/µL, HIV-1 RNA 645,000 copies/mL) who presented with 2 weeks of widespread mucocutaneous disease, circumferential necrotic penile ulceration with severe dysuria, and periocular involvement. Mpox was confirmed by real-time PCR from multiple anatomical sites, with sequencing identifying Clade I (subclade Ib) infection. Longitudinal sampling showed consistently low Ct values in skin and genital lesions despite rising salivary Ct values, indicating differential compartmental viral clearance. Serial pus cultures from ulcerated lesions yielded multi-resistant gram-negative bacilli and coagulase-negative staphylococci, with sustained resistance to first-line agents throughout the clinical course. Meropenem remained the only antimicrobial to which isolates were consistently susceptible across all sampling points, suggestive of evolving polymicrobial wound colonisation under antibiotic selection pressure. Management and outcome: Empirical ceftriaxone and metronidazole proved ineffective. Culture-guided escalation to intravenous meropenem, along with intensive wound care, pain management, ocular prophylaxis, and resumption of antiretroviral therapy (ART), resulted in gradual clinical improvement. The patient was discharged after 4 weeks with healed skin lesions and mild residual ocular discomfort. At 3 months, immune reconstitution was observed (CD4 173 cells/µL; HIV-1 RNA 72 copies/mL) with complete functional recovery. Conclusions: Severe Clade Ib (subclade Ib) mpox in advanced HIV can present with genital necrosis, ocular involvement, persistent lesion-site viral burden, and multidrug-resistant bacterial superinfection. Even in the absence of specific antivirals, favourable outcomes can be achieved through integrated HIV care, early culture-guided antimicrobial stewardship, and proactive ocular management.
- 24 June 2026
- Published by Springer Nature in Tropical Medicine and Health
Open AccessSevere Clade I (subclade Ib) mpox in advanced HIV complicated by multidrug-resistant bacterial superinfection and ocular involvement: a case report from Uganda
Background: Mpox in people living with HIV (PLHIV) with advanced immunosuppression is poorly understood in sub-Saharan Africa, where high HIV prevalence intersects with limited access to mpox-specific antivirals. Urgent evidence is needed to guide clinical management and improve outcomes for this vulnerable population in resource-limited settings with outbreaks. Case presentation: We report a 30-year-old Ugandan man with advanced HIV (CD4 55 cells/µL, HIV-1 RNA 645,000 copies/mL) who presented with 2 weeks of widespread mucocutaneous disease, circumferential necrotic penile ulceration with severe dysuria, and periocular involvement. Mpox was confirmed by real-time PCR from multiple anatomical sites, with sequencing identifying Clade I (subclade Ib) infection. Longitudinal sampling showed consistently low Ct values in skin and genital lesions despite rising salivary Ct values, indicating differential compartmental viral clearance. Serial pus cultures from ulcerated lesions yielded multi-resistant gram-negative bacilli and coagulase-negative staphylococci, with sustained resistance to first-line agents throughout the clinical course. Meropenem remained the only antimicrobial to which isolates were consistently susceptible across all sampling points, suggestive of evolving polymicrobial wound colonisation under antibiotic selection pressure. Management and outcome: Empirical ceftriaxone and metronidazole proved ineffective. Culture-guided escalation to intravenous meropenem, along with intensive wound care, pain management, ocular prophylaxis, and resumption of antiretroviral therapy (ART), resulted in gradual clinical improvement. The patient was discharged after 4 weeks with healed skin lesions and mild residual ocular discomfort. At 3 months, immune reconstitution was observed (CD4 173 cells/µL; HIV-1 RNA 72 copies/mL) with complete functional recovery. Conclusions: Severe Clade Ib (subclade Ib) mpox in advanced HIV can present with genital necrosis, ocular involvement, persistent lesion-site viral burden, and multidrug-resistant bacterial superinfection. Even in the absence of specific antivirals, favourable outcomes can be achieved through integrated HIV care, early culture-guided antimicrobial stewardship, and proactive ocular management.
- Open Access
- 24 June 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 170, 108919
Clinical and microbiological features of critical Clade Ib mpox in adults with HIV during a Ugandan outbreak
- 24 June 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 170, 108919
Open AccessClinical and microbiological features of critical Clade Ib mpox in adults with HIV during a Ugandan outbreak
- Open Access
- 20 May 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (5) , e0341642
Practical guidelines for producing non-replicating canine adenovirus vectors
Adenovirus vectors have been used for vaccine development, gene therapy, among others, because of their ease of genetic manipulation and high efficiency in delivering and expressing genes in mammalian cells without causing significant cytotoxicity or integrating into the host genome. Adenovirus vectors are relatively immunogenic, hence avoiding the need for adjuvant when used in vaccine design, unlike other vaccine development platforms. Human adenovirus serotype 5 (HAdV-5) has traditionally been employed in vaccine platforms; however, its clinical utility is limited by widespread pre-existing immunity in human populations, which can reduce vaccine efficacy. As a promising alternative, canine adenovirus type 2 (CAV-2) vector offers several advantages, including low seroprevalence in humans, efficient infection of respiratory epithelial and neuronal cells, and long-lasting transgene expression. These features render the CAV-2 vector particularly suitable for vaccine applications requiring repeated administrations or booster doses. In this protocol, we describe methods for the expression, expansion, purification, and titration of a non-replicative CAV-2 vector in the AD-293 cell line. The procedure involves the release of the recombinant viral genome from the pUC19 plasmid backbone, followed by virus stock expansion in a complementing AD-293 cell line, which is able to express the E1 protein to aid virus replication. The virus stock was purified through ion-exchange liquid chromatography and titered using the Improved Kärber method. This work contributes to the growing field of alternative adenoviral vectors with implications for translational research by providing step-by-step procedures for producing a canine adenovirus type 2 (CAV-2) vector.
- 20 May 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (5) , e0341642
Open AccessPractical guidelines for producing non-replicating canine adenovirus vectors
Adenovirus vectors have been used for vaccine development, gene therapy, among others, because of their ease of genetic manipulation and high efficiency in delivering and expressing genes in mammalian cells without causing significant cytotoxicity or integrating into the host genome. Adenovirus vectors are relatively immunogenic, hence avoiding the need for adjuvant when used in vaccine design, unlike other vaccine development platforms. Human adenovirus serotype 5 (HAdV-5) has traditionally been employed in vaccine platforms; however, its clinical utility is limited by widespread pre-existing immunity in human populations, which can reduce vaccine efficacy. As a promising alternative, canine adenovirus type 2 (CAV-2) vector offers several advantages, including low seroprevalence in humans, efficient infection of respiratory epithelial and neuronal cells, and long-lasting transgene expression. These features render the CAV-2 vector particularly suitable for vaccine applications requiring repeated administrations or booster doses. In this protocol, we describe methods for the expression, expansion, purification, and titration of a non-replicative CAV-2 vector in the AD-293 cell line. The procedure involves the release of the recombinant viral genome from the pUC19 plasmid backbone, followed by virus stock expansion in a complementing AD-293 cell line, which is able to express the E1 protein to aid virus replication. The virus stock was purified through ion-exchange liquid chromatography and titered using the Improved Kärber method. This work contributes to the growing field of alternative adenoviral vectors with implications for translational research by providing step-by-step procedures for producing a canine adenovirus type 2 (CAV-2) vector.
- Open Access
- 3 April 2026
- Published by Elsevier in SSRN Electronic Journal
Critical Clade Ib Mpox in Adults with HIV in Uganda: A Prospective Observational Study of Viral Burden, Lesion Microbiology, and Inflammatory Markers
Background: Severe mpox in people living with HIV remains poorly characterised in African referral settings experiencing Clade 1b transmission. We investigated the clinical and biological features of critical illness during the 2025 Clade 1b mpox outbreak in Uganda. Methods: We conducted a prospective observational study nested within a consecutive cohort of 155 adults admitted to Entebbe Regional Referral Hospital, Uganda, with suspected or confirmed mpox between 3 March and 10 April 2025. Participants with predefined critical illness and laboratory-confirmed Clade 1b infection underwent compartment-specific mpox PCR testing, lesion bacterial culture with antimicrobial susceptibility testing, HIV viral load assessment, and routine haematology and biochemistry. Analyses were descriptive, given the small sample size and exploratory nature of the study. Findings: Ten of 155 hospitalised adults (6.5%) developed critical illness; four died, four had severe disease, and two required intensive care. All were people living with HIV. At approximately 14 days post-symptom onset, mpox DNA was consistently detected in skin, genital, and oral or saliva specimens with low cycle threshold values, whereas plasma detection was infrequent and occurred at higher values. Purulent lesion cultures were positive in 9/9 participants, yielding Gram-negative bacilli, Staphylococcus aureus, coagulase-negative staphylococci, and Enterococcus species, with broad resistance to commonly used antimicrobial classes; meropenem retained activity. Critically ill participants demonstrated an inflammatory profile with anaemia, neutrophilia with relative lymphopenia, hypoalbuminaemia, hyperbilirubinaemia, and elevated C-reactive protein. Survivors demonstrated near-complete viral clearance; one participant with persistent plasma and anal positivity died. Interpretation: Critical Clade 1b mpox was characterised by dominant mucocutaneous viral burden, frequent bacterial growth with antimicrobial resistance, and systemic inflammatory derangement in people with HIV, supporting integrated triage, antimicrobial stewardship, and inpatient management strategies.
- 3 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessCritical Clade Ib Mpox in Adults with HIV in Uganda: A Prospective Observational Study of Viral Burden, Lesion Microbiology, and Inflammatory Markers
Background: Severe mpox in people living with HIV remains poorly characterised in African referral settings experiencing Clade 1b transmission. We investigated the clinical and biological features of critical illness during the 2025 Clade 1b mpox outbreak in Uganda. Methods: We conducted a prospective observational study nested within a consecutive cohort of 155 adults admitted to Entebbe Regional Referral Hospital, Uganda, with suspected or confirmed mpox between 3 March and 10 April 2025. Participants with predefined critical illness and laboratory-confirmed Clade 1b infection underwent compartment-specific mpox PCR testing, lesion bacterial culture with antimicrobial susceptibility testing, HIV viral load assessment, and routine haematology and biochemistry. Analyses were descriptive, given the small sample size and exploratory nature of the study. Findings: Ten of 155 hospitalised adults (6.5%) developed critical illness; four died, four had severe disease, and two required intensive care. All were people living with HIV. At approximately 14 days post-symptom onset, mpox DNA was consistently detected in skin, genital, and oral or saliva specimens with low cycle threshold values, whereas plasma detection was infrequent and occurred at higher values. Purulent lesion cultures were positive in 9/9 participants, yielding Gram-negative bacilli, Staphylococcus aureus, coagulase-negative staphylococci, and Enterococcus species, with broad resistance to commonly used antimicrobial classes; meropenem retained activity. Critically ill participants demonstrated an inflammatory profile with anaemia, neutrophilia with relative lymphopenia, hypoalbuminaemia, hyperbilirubinaemia, and elevated C-reactive protein. Survivors demonstrated near-complete viral clearance; one participant with persistent plasma and anal positivity died. Interpretation: Critical Clade 1b mpox was characterised by dominant mucocutaneous viral burden, frequent bacterial growth with antimicrobial resistance, and systemic inflammatory derangement in people with HIV, supporting integrated triage, antimicrobial stewardship, and inpatient management strategies.
- Open Access
- 19 January 2026
- Published by F1000 Research Ltd in VeriXiv
Saliva PCR Performs Comparably to Lesion Swabs for Acute-Phase Clade Ib Mpox Diagnosis in Uganda: Evidence from a Matched Hospital Cohort
- 19 January 2026
- Published by F1000 Research Ltd in VeriXiv
Open AccessSaliva PCR Performs Comparably to Lesion Swabs for Acute-Phase Clade Ib Mpox Diagnosis in Uganda: Evidence from a Matched Hospital Cohort